Casio America, Inc. re-entered the professional synthesizer market this year with the launch of two products ideal for performing and recording artists – the XW-P1 Performance Synthesizer and the XW-G1 Groove Synthesizer. Based on the successful introduction of the XW series, Casio has teamed up with aNYthing, a streetwear/lifestyle brand located in New York City, to create a limited edition XW-P1 synthesizer. Designed in a signature gold hue, only 200 XW-P1GD units will be available at Guitar Center and Musician’s Friend.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57776-casio-anything-xw-p1-performance-synthesizer-and-xw-g1-groove-synthesizer
What do you think of this music video? Love can really drive some people to do crazy things! The main character in this story only wants the best for her man, even if it means going into an area that is off limits; his sacred garage.
http://www.facebook.com/DIYNetwork
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory released results today from a new survey which showed that more than half (59 percent) of nasal allergy sufferers polled reported sleep issues as a result of their allergy symptoms, yet only 35 percent proactively treat their nasal allergy symptoms. Furthermore, nearly half of those surveyed (48 percent) said their nasal allergy symptoms, such as nasal congestion and sneezing, also interrupted their partner’s sleep.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60975-teva-respiratory-aafa-ditch-the-drip-misty-may-treanor-nasal-allergies
A recent study found that only 47% of Americans are currently taking steps to prevent bone loss1, despite considering it to be of high importance. In an effort to educate the public about the importance of bone health, Sunsweet Growers has partnered with the International Osteoporosis Foundation (IOF) to support their annual World Osteoporosis Day (WOD) campaign. WOD is globally celebrated on October 20 and serves to create awareness for bone health and the steps that can be taken to protect bones including incorporating bone-building habits – like eating prunes – into a regular lifestyle routine.
Bones need the right nutrients to stay strong and healthy and research suggests that eating just 5-6 prunes (the Feel Good Fruit!) each day may help to prevent bone loss. However, many do not think about bone health until after a fracture or break occurs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8410051-sunsweet-iof-world-osteoporosis-day-bone-health/
As facts go, we’re used to extraordinary numbers in the tech world, yet certain realities continue to astonish: each day on the planet, more iPhones are sold than babies are born. Access to information is constantly at our fingertips, keeping us connected virtually at all times; but moments when we are face-to-face merit attention as well. Kendall-Jackson, a family-owned winery that handcrafts high-quality wines, is changing the way wine can be part of those everyday occasions with family and friends. Introducing “Goes Well With Friends,” your official permission to enjoy wine however, whenever and with whomever you choose. Instead of only pairing wine with food, Kendall-Jackson invites you to pair wine selections with your experiences and mood, such as a night out with friends, a quiet dinner for two or a family gathering.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58948-kendall-jackson-discover-k-j-recommends-wine-app
Tried and tested that Lithium ion batt is the only thing that can give life to a lonely, lifeless and poor CP. This clip proves it. This is the best clip! Two thumbs up! Vote Now!
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
In an effort to support the health and wellness of its guests nationwide, Dickey’s Barbecue Pit has announced that all meats sold in every location will contain “No B.S.” (Bad Stuff) by sourcing only responsibly raised, quality meats. Starting August 15, all chicken sold will now be raised without antibiotics. This breakthrough in sustainability not only comprises the brand’s traditional slow smoked chicken breast, but also will include whole smoked chickens and chicken nuggets served in kids’ meals at select stores. To learn more, click here.
The chicken is 100% vegetarian fed and humanely raised. It is also completely hormone-free and cage-free, ensuring that Dickey’s guests are served only the highest quality poultry with no additives. This announcement accompanies other advances in sustainability by the barbecue brand including humanely handled and sustainably raised brisket as well as locally-made sausage with no nitrates, nitrites* or artificial coloring or flavors. Additionally, all of Dickey’s pork products are free from added hormones**, nitrates, nitrites* and artificial coloring and flavors.
To view the multimedia release go to:
http://www.multivu.com/players/English/7717951-dickeys-barbecue-pit-no-bad-stuff-initiative/
New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
DEWALT unveils the FLEXVOLT™ system, which features the world’s first battery that automatically changes voltage when the user changes tools. The FLEXVOLT™ battery powers a new lineup of brushless 60V MAX* and 120V MAX* FLEXVOLT™ tools. What makes the FLEXVOLT™ battery (DCB606) extremely innovative is its patent-pending technology that is backwards compatible with most existing DEWALT 20V MAX* tools and chargers. When used in DEWALT 20V MAX* tools, the FLEXVOLT™ battery provides up to 4X runtime**. In addition, the FLEXVOLT™ battery provides more than 3X battery power versus DEWALT 18V NiCad.
The key to this technology is the ability of the FLEXVOLT™ battery to switch between DEWALT tools of varying voltages (20V MAX*, 60V MAX* and 120V MAX*). The FLEXVOLT™ battery automatically changes voltage depending on whether it’s being used in a 20V MAX* or 60V MAX* tool. Two FLEXVOLT™ batteries together power the new DEWALT 120V MAX* tools. This means that high power tool applications that previously could only be accomplished by corded tools, can now be performed with the DEWALT FLEXVOLT™ system of cordless tools. As a result of this advanced battery technology, jobsites can now fully transition from corded to the freedom of cordless.
To view the multimedia release go to:
http://www.multivu.com/players/English/7517855-dewalt-unveils-flexvolt-system/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
